Skip to content
Search

Latest Stories

Reliance launches JioMeet to take on Zoom

INDIA's Reliance has launched JioMeet video conferencing app with unlimited free calling facility and starts a rate war on rival Zoom. It is available across Android, iOS, Windows, macOS and web, the company said.

JioMeet supports HD audio and video call quality with up to 100 participants and offers features like screen sharing, meeting schedule feature and more. Unlike Zoom, it does not impose a 40-minute time limit. Calls can go on as long as 24 hours, and all meetings are encrypted and password-protected, the company said.


While Reliance provides the facility for free, Zoom charges $15 per month ($180 per year)for meetings of more than 40 minutes.

According to details given on the website, JioMeet offers easy sign up with either mobile number or e-mail ID and allows creation of instant meeting. The meeting in HD audio and video quality can be scheduled in advance and details shared with invitees.

Each meeting is password protected and the host can enable 'Waiting Room' to ensure no participant joins without permission. It also allows creation of groups and starting calling/chatting on a single click.

The app has already seen more than 500,000 downloads on the Google Play Store and iOS. It should be noted that India recently banned 59 popular Chinese apps including TikTok on grounds that they threatened national security and data privacy.

JioMeet app allows national and international seminars as well as hosting of cultural and social events. Unlike Zoom, JioMeet users can switch from one device to another without dropping out of the call. It allows nine active participants on a single mobile screen whereas Zoom allows only four.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less